Abram Scientific

Executive Summary

Abram Scientific is a US-based biotechnology company developing fast point-of-care (POC) coagulation diagnostics to improve hemostasis management. Founded in 2018 and headquartered in Cambridge, the company focuses on precision blood management solutions that deliver rapid, actionable data at the point of care. By addressing the need for real-time coagulation testing, Abram Scientific aims to reduce turnaround times and enhance clinical outcomes in settings such as emergency rooms, operating rooms, and intensive care units. The company's technology leverages proteomics to assess clotting function, potentially enabling faster clinical decisions and reducing reliance on central lab testing. As a private entity with no disclosed funding rounds or commercial products, Abram Scientific is in an early stage, but its focus on a clear unmet need in coagulation diagnostics positions it within a growing market for POC testing. The success of the company will hinge on regulatory clearances, clinical validation, and commercial partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for initial POC coagulation device60% success
• Q2 2026Series A funding round to support clinical trials and manufacturing70% success
• Q3 2026Strategic partnership with a major hospital network for pilot studies50% success